{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:33:35Z","timestamp":1791894815931,"version":"4.3.4"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,6,15]]},"DOI":"10.2169\/internalmedicine.9851-17","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T22:19:19Z","timestamp":1518128359000},"page":"1789-1792","source":"Crossref","is-referenced-by-count":30,"title":["Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma"],"prefix":"10.2169","volume":"57","author":[{"given":"Tokuhiro","family":"Matsubara","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Higaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Shimakoshi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Osugi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Nakamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Inada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.","DOI":"10.1038\/nrc3239"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 8: 410-416, 2017.","DOI":"10.7150\/jca.17144"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372: 2006-2017, 2015.","DOI":"10.1056\/NEJMoa1414428"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35: 529-536, 2017.","DOI":"10.1007\/s10637-017-0453-0"},{"key":"5","unstructured":"5. Gelsomino F, Vitale G, D&apos;Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28: 671-672, 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.","DOI":"10.1056\/NEJMoa1200690"},{"key":"7","unstructured":"7. Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 28 (Suppl): 30-38, 2014."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33: 1430-1437, 2015.","DOI":"10.1200\/JCO.2014.59.0703"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16: 257-265, 2015.","DOI":"10.1016\/S1470-2045(15)70054-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015.","DOI":"10.1056\/NEJMoa1504627"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hodi FS, O&apos;Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.","DOI":"10.1056\/NEJMoa1003466"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15: 700-712, 2014.","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16: 522-530, 2015.","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532, 2015.","DOI":"10.1056\/NEJMoa1503093"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697, 2012.","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf 14: 1507-1518, 2015.","DOI":"10.1517\/14740338.2015.1085969"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li H, Ma W, Yoneda KY, et al. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol 10: 64, 2017.","DOI":"10.1186\/s13045-017-0433-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/12\/57_9851-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T03:58:44Z","timestamp":1529121524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/12\/57_9851-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9851-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]}}}